price oct usd
path sale recoveri
hold rate reect view see less room upsid
ep estim multipl expans versu peer given believ
rel mute margin expans opportun lack notabl product
cycl drive revenu acceler result lower
adjust ep guidanc support thesi
thing like
focus put balanc sheet work target upsiz
share repo intend place increas focu put
balanc sheet work primarili signic acceler
share repurchas activ inde compani expect acceler
repurchas activ continu acceler fy
manag target net leverag ratio fy end
versu net cash posit believ impli
capit deploy capac major expect
share repurchas activ compani also signal increas
willing evalu inorgan growth opportun enhanc
product portfolio expect increment deal focus tuck-
in howev believ remain avers larg deal
growth china busi strength driven pharma food
ne chemic end market partial oset soft ta busi
thing cautiou
fy guidanc lower sale growth adjust ep guid
consensu lower fy outlook organ sale
growth adjust ep perform across sever market
product categori came expect lower fy
organ sale growth guid rang
adjust ep guidanc rang
midpoint organ sale growth guid rang
meaning consensu adjust ep guidanc
rang consensu
biopharma growth disappoint biopharma growth
deceler prior quarter advers impact
soft european end market growth look particularli poor
distribut gmt
deutsch bank seek busi compani cover research report thu investor
awar rm may conict interest could aect object report investor consid
report singl factor make invest decis disclosur analyst certif
light mid-teen biopharma growth report last week
high singl digit growth sciex busi manag attribut
slowdown tough prior year compar well lower demand
level relat brexit uncertainti expect rebound
note sartoriu group satg gunnar romer releas
result today ag softer demand europ lab product
servic divis posit side note us pharma
activ rebound quarter follow slow start
india progress slower expect outlook incorpor mute
expect india busi grew modestli slower-
than-expect progress led moder near-term
outlook manag also call custom hesit around
recent indian rupe devalu well upcom elect
believ soft could carri fy
sign instrument shipment delay us china sale growth
ta divis advers impact delay product ship
china manag hesit attribut escal
trade tension us china compani note evid
increas delay order sale expect watch
close note ta product line one product
line ship china us
industri end market growth slow industri food safeti end
market sale deceler quarter manag
attribut slowdown product line delay ta busi
suer delay shipment china said note
order growth encourag consist year-to-d trend
expect much delay normal
lower pt reect lower estim group multipl
lower pt new pt reect
enterpris valu use project level debt cash
ttm ebitda ex option reect
lower valuat multipl group multipl discount life
scienc tool peer group median ev/ftm ebitda ex option think
reason given secular growth prospect limit margin expans
forecast ratio
period end incom expens ep share share sale cash flowoper cash cash constant conform compani present includ expens intang amort ex- acquir amort
period end asset equival st receiv expens current current equip asset asset liabil current portion long-term current debt less current long-term liabil stockhold octob
